Actavis (ACT) PT Lifted to $352 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Actavis (ACT) PT Lifted to $352 at Canaccord Genuity
February 20, 2015 9:32 AM EST
Argus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock... More
February 20, 2015 8:46 AM EST
Actavis (NYSE: ACT) announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex® (Buprenorphine 2 mg and 8 mg sublingual tablets). Actavis intends to begin shipping... More
February 18, 2015 4:23 PM EST
Guggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from $300.00) following Q4 results and outlook.
Chen comments, "We are raising our PT to $345 from $300 post a 4Q14 beat and strong outlook for '15. We use a... More
